Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 1, 2025, reports a transaction in the company's own shares. The filing covers a specific share repurchase event executed on April 30, 2025, acting through corporate stockbroker Citigroup Global Markets Limited.
Key Financial Metrics
- Shares Purchased: 695,650 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,427.50 GBp; highest price paid was 1,504.50 GBp.
- Average Price: Volume-weighted average price paid was 1,485.05 GBp.
- Treasury Shares: Following this purchase, GSK holds 204,800,108 ordinary shares in treasury.
- Shares in Issue: 4,110,441,270 ordinary shares (excluding Treasury shares).
- Voting Rights: Total voting rights stand at 4,110,441,270.
Material Changes and Program Status
The purchase was part of GSK's existing buyback programme, executed pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this agreement on February 24, 2025, the Company has purchased an aggregate of 35,729,805 ordinary shares. All purchased shares are held as Treasury shares.
Outlook, Risks, and Management Commentary
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific factors include those described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and GSK's Q1 Results for 2025. No specific new guidance or unusual items were disclosed in this transaction report.
Investor Verification Checklist
- Verify the total number of shares purchased under the current buyback programme (35,729,805 since Feb 24, 2025).
- Confirm the updated count of Treasury shares (204,800,108) and shares in issue (4,110,441,270) for voting rights calculations.
- Review the "Risk Factors" in the 2024 Form 20-F and Q1 2025 results for context on forward-looking statements.
- Note that the filing does not provide revenue, profit, or cash flow data; it is strictly a disclosure of share repurchase activity.